drugset / Trial / NCT00752973
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
Timeline
- Start
- 2008-09
- Primary completion
- 2011-12
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Malathion | Small molecule | 0.5 % | Topical |